[76] [77] In a 72-week, phase IIIb open-label head-to-head trial of adults with obesity without diabetes, tirzepatide at the maximum tolerated dose produced greater mean weight loss than semaglutide and larger reductions in waist circumference, while gastrointestinal adverse events were the most common with both drugs
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
Another test is often done around the eight-week mark to confirm that the treatment has successfully corrected the deficiency
Cell 160(5):829841 Nakazato M et al (2001) A role for ghrelin in the central regulation of feeding
Evidence also suggests it slows kidney disease progression
But if you're dealing with inflammation, want cardiovascular protection, and prefer not to compromise how you feel physically, GLP-1s offer a more complete solution